Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2006 4
2007 1
2008 2
2009 4
2010 4
2011 4
2012 3
2014 6
2015 6
2016 6
2017 11
2018 12
2019 16
2020 10
2021 11
2022 8
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
The KNOW-CKD Study: What we have learned about chronic kidney diseases.
Oh KH, Kang M, Kang E, Ryu H, Han SH, Yoo TH, Kim SW, Chae DW, Lee KB, Park SK, Kim YH, Ahn C; KNOW-CKD Study Investigators. Oh KH, et al. Among authors: lee kb. Kidney Res Clin Pract. 2020 Jun 30;39(2):121-135. doi: 10.23876/j.krcp.20.042. Kidney Res Clin Pract. 2020. PMID: 32550711 Free PMC article. Review.
Urinary Potassium Excretion and Progression of CKD.
Kim HW, Park JT, Yoo TH, Lee J, Chung W, Lee KB, Chae DW, Ahn C, Kang SW, Choi KH, Han SH; KNOW-CKD Study Investigators. Kim HW, et al. Among authors: lee kb. Clin J Am Soc Nephrol. 2019 Mar 7;14(3):330-340. doi: 10.2215/CJN.07820618. Epub 2019 Feb 14. Clin J Am Soc Nephrol. 2019. PMID: 30765533 Free PMC article.
Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease.
Yun HR, Joo YS, Kim HW, Park JT, Chang TI, Son NH, Yoo TH, Kang SW, Sung S, Lee KB, Lee J, Oh KH, Han SH; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) investigators; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Yun HR, et al. Among authors: lee kb. J Am Soc Nephrol. 2022 Aug;33(8):1590-1601. doi: 10.1681/ASN.2022010080. Epub 2022 Jun 2. J Am Soc Nephrol. 2022. PMID: 35654602 Free PMC article.
107 results